Article citationsMore>>

Kimball, A.B., Jemec, G.B.E., Sayed, C.J., Kirby, J.S., Prens, E., Ingram, J.R., et al. (2024) Efficacy and Safety of Bimekizumab in Patients with Moderate-to-Severe Hidradenitis Suppurativa (BE HEARD I and BE HEARD II): Two 48-Week, Radomised, Double-Blind, Placebo-Controlled, Multicentre Phase 3 Trials. The Lancet, 403, 2504-2519.
https://doi.org/10.1016/s0140-6736(24)00101-6

has been cited by the following article:

• TITLE: Research Advances in the Treatment of Hidradenitis Suppurativa

  AUTHORS: Zhenyu Luo, Mengfan Lu, Jin Gong

  KEYWORDS: Hidradenitis Suppurativa, Pharmacotherapy, Surgical Treatment, Physical Therapy

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.13 No.5, May 13, 2025

  ABSTRACT: Hidradenitis suppurativa (HS) is a refractory and recurrent chronic inflammatory skin disease characterized by nodules, abscesses, sinus tracts, and scarring. The etiology of HS remains unclear, rendering its treatment particularly challenging. Current therapeutic approaches encompass lifestyle modifications, topical medications, conventional systemic drugs, biologic agents, surgical interventions, and traditional Chinese medicine (TCM). A personalized treatment strategy tailored to individual patient characteristics is essential to achieve optimal clinical outcomes.